![CDATA[ [if IE 9] ]]>
If Hepatitis B Panel results are “Reactive” then Hepatitis B Core Antibody IgM will be performed.
Hepatitis B is a viral illness that is transmitted through blood and other body fluids. Both acute and chronic stages occur, with the frequency of progression to chronicity declining with age at time of infection. Chronic hepatitis B often leads to cirrhosis and hepatocellular carcinoma. Hepatitis B is a vaccine-preventable disease.
Limitations • The results determined by different assays from different manufacturers can vary due to differences in assay specificities and cannot be used interchangeably. • The performance of the assay has not been established with cord blood, neonatal specimens, infants, children, or adolescent patients, immunocompromised, immunosuppressed, cadaver specimens, heat-inactivated specimens, or body fluids. • A reactive Anti-Hepatitis B core Total result does not exclude co-infection by another hepatitis virus.
Interpretation of panel results is as follows:
HBsAg -Hepatitis B surface antigen; HBsAb - Hepatitis B surface antibody; HBcAb (total) - Hepatitis B core total antibody.
In cases where the HBcAb (total) component is reactive, a hepatitis B core IgM antibody (HBcAb, IgM) test will be performed with an added charge: a reactive HBcAb,IgM result is consistent with acute hepatitis B, while a non-reactive HBcAb,IgM result is consistent with either post-acute convalescent or chronic hepatitis B.